Mankind Pharma Limited announced the approval of two significant amalgamation schemes by its Board of Directors on October 26, 2026. Scheme 1 involves the amalgamation of wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into Mankind Pharma Limited. Scheme 2 involves the amalgamation of Upakarma Ayurveda Private Limited into Mankind Consumer Products Private Limited. These schemes aim to streamline corporate structure and enhance operational efficiencies.
Mankind Pharma Board Approves Key Amalgamation Schemes
On October 26, 2026, the Board of Directors of Mankind Pharma Limited convened and approved two crucial Scheme of Arrangements for amalgamation. These strategic moves are designed to simplify the company’s corporate structure and optimize operational efficiencies.
Scheme 1: Consolidation of Wholly Owned Subsidiaries
The first approved scheme (Scheme 1) involves the amalgamation of Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited, both wholly owned subsidiaries of Mankind Pharma Limited, into the parent company, Mankind Pharma Limited. This transaction is intended to rationalize the existing group structure, reduce the number of legal entities, and create a more streamlined corporate framework. The Appointed Date for this amalgamation is set as April 01, 2027.
Scheme 2: Amalgamation of Upakarma Ayurveda
The second approved scheme (Scheme 2) focuses on the amalgamation of Upakarma Ayurveda Private Limited (Transferor Company) with and into Mankind Consumer Products Private Limited (Transferee Company). This amalgamation aims to consolidate business operations, leading to enhanced operational integration and efficient management. The approved scheme was also noted by the respective Boards of Directors of Upakarma Ayurveda Private Limited and Mankind Consumer Products Private Limited on the same date.
Financial Results and Auditor Reports
In addition to the amalgamation approvals, the Board also approved the unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The Limited Review Reports from the joint statutory auditors, M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., were also enclosed. The financial statements indicate a strong performance for the period, with total income for the quarter reaching ₹3,204.05 crores and for the six months at ₹6,202.06 crores.
Source: BSE
